Forbion
Overview
Forbion is a global venture capital firm that invests in life sciences and bioeconomy companies, managing multiple fund strategies across all stages of drug development.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| OMass Therapeutics | Oct 2026 | Series C | Lead |
| Sling Therapeutics | Sep 2026 | Series C | Lead |
| Solstice Oncology | Sep 2026 | Series A | Co-investor |
| Kynexis Therapeutics | Aug 2026 | Series A | Co-investor |
| Expedition Therapeutics | Aug 2026 | Series B | Co-investor |
For institutional investors. Book with your work email.
Key People
Geert-Jan Mulder
Managing Partner
Martien van Osch
Managing Partner
Sander Slootweg
Co-owner and Managing Partner
Alexander Hoffmann
General Partner
Dmitrij Hristodorov
General Partner
Jasper Bos
General Partner
Nanna Lüneborg
General Partner
Wouter Joustra
General Partner
Carlo Incerti
Operating Partner
Gijs van den Brink
Operating Partner
John Montana
Operating Partner
Rory Gummerson
Operating Partner
Avi Molcho
Venture Partner
Goekben Koca
Venture Partner
Jens Wendland
Venture Partner
Jonathan McNeill
Venture Partner
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Forbion based?
Forbion is headquartered in Naarden, Netherlands.
When was Forbion founded?
Forbion was founded in 2006.
How many portfolio companies does Forbion have?
Forbion has 65 portfolio companies in Caplight's dataset.
What are some companies in Forbion's portfolio?
Recent investments visible on Caplight include OMass Therapeutics, Sling Therapeutics, Solstice Oncology, Kynexis Therapeutics, Expedition Therapeutics.
What was Forbion's most recent investment?
Forbion's most recent investment on Caplight was in OMass Therapeutics in 2026.
What sectors does Forbion focus on?
Forbion focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Frontier & Industrial Tech, Energy & Sustainability, Energy & Sustainability, Energy & Sustainability, Frontier & Industrial Tech, Energy & Sustainability, Healthcare & Life Sciences, Consumer & Commerce, Frontier & Industrial Tech, Frontier & Industrial Tech, Frontier & Industrial Tech, AI, Data & Cloud Infrastructure.
What company stages does Forbion focus on?
Stage focus information for Forbion is not publicly available.
What is Forbion's AUM?
Forbion's assets under management are estimated between $5.5B and $5.5B.